NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma
NCT ID: NCT06420349
Last Updated: 2025-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
7 participants
INTERVENTIONAL
2024-05-31
2025-09-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To determine the maximum tolerated dose (MTD)/recommended phase 2 dose for heat shock factor 1 pathway inhibitor NXP800 (NXP800).
SECONDARY OBJECTIVES:
I. To determine the toxicity profile of NXP800. II. To determine the best response for NXP800 using Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1.
III. To estimate the overall survival (OS) for NXP800. IV. To estimate the progression-free survival (PFS) for NXP800.
EXPLORATORY OBJECTIVES:
I. To evaluate transcriptomic features associated with sensitivity, resistance and pharmacodynamic effect of NXP800 using serial ribonucleic acid-sequencing (RNA-Seq).
II. To assess tumor evolution with NXP800 using serial whole genome-sequencing (Seq).
III. To assess tumor evolution with NXP800 using serial circulating tumor deoxyribonucleic acid (DNA) (ct-DNA).
IV. To estimate tumor marker response using serial CA19-9/carcinoembryonic antigen (CEA).
OUTLINE: This is a dose de-escalation study of NXP800 followed by a dose-expansion study.
Patients receive NXP800 orally (PO) according to assigned treatment schedule. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT), magnetic resonance imaging (MRI), and/or positron emission tomography (PET) at baseline and on study. Patients may optionally undergo ultrasound-guided tumor biopsy and/or collection of blood samples on study and during follow up.
After completion of study treatment, patients are followed up every 6 months until progressive disease or death for up to 3 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (NXP800)
Patients receive NXP800 according to assigned treatment schedule. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or PET at baseline and on study. Patients may optionally undergo ultrasound-guided tumor biopsy and/or collection of blood samples on study and during follow up.
Biospecimen Collection
Undergo collection of blood samples
Computed Tomography
Undergo CT
Heat Shock Factor 1 Pathway Inhibitor NXP800
Given PO
Magnetic Resonance Imaging
Undergo MRI
Positron Emission Tomography
Undergo PET
Ultrasound-Guided Biopsy
Undergo ultrasound-guided tumor biopsy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biospecimen Collection
Undergo collection of blood samples
Computed Tomography
Undergo CT
Heat Shock Factor 1 Pathway Inhibitor NXP800
Given PO
Magnetic Resonance Imaging
Undergo MRI
Positron Emission Tomography
Undergo PET
Ultrasound-Guided Biopsy
Undergo ultrasound-guided tumor biopsy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically/cytologically confirmed biliary tract cancer
* Advanced or metastatic disease that is refractory to gemcitabine or fluoropyrimidine based therapy, or if there is intolerance to these regimens
* Measurable disease by RECIST 1.1
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
* Anticipated life expectancy of \> 12 weeks
* Hemoglobin ≥ 9.0 g/dL (obtained ≤ 14 days prior to registration)
* Absolute neutrophil count (ANC) ≥ 1500/mm\^3 (obtained ≤ 14 days prior to registration)
* Platelet count ≥ 100,000/mm\^3 (obtained ≤ 14 days prior to registration)
* Aspartate aminotransferase (AST) ≤ 5 x upper limit of normal (ULN) (obtained ≤ 14 days prior to registration)
* Alanine aminotransferase (ALT) ≤ 5 x ULN (obtained ≤ 14 days prior to registration)
* Total bilirubin ≤ 1.5 x ULN (obtained ≤ 14 days prior to registration)
* Serum creatinine ≤ 1.5 x ULN (obtained ≤ 14 days prior to registration)
* Provide written informed consent
* Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only
* NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
* Willing to use a highly effective method of contraception from the first dose of study medication through 180 days after the last dose of study medication, for persons of childbearing potential or persons able to father a child only
* Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Exclusion Criteria
* Pregnant persons.
* Nursing persons.
* Persons of childbearing potential who are unwilling to employ adequate contraception
* Systemic anti-neoplastic therapy or radiation therapy ≤ 14 days prior to registration
* Major surgical procedure ≤ 28 days prior to registration
* Ongoing therapy related events \> grade 2
* Presence of another primary malignancy not in remission
* New York Heart Classification 3 or greater heart failure
* QT/corrected QT (QTc) interval \> 470 ms using Fredericia's QT correction formula
* Uncontrolled brain metastatic disease
* Uncontrolled infection
* Any other comorbidities within the opinion of the investigator interfere with the investigation of the protocol
* Usage of drugs that strongly inhibit or induce CYP3A4 ≤ 7 days prior to registration and for the duration of NXP800 dosing. Drugs that are low, medium, or other inhibitors of CYP3A4 are not prohibited and should be used with caution. Drugs that inhibit BCRP are not prohibited but should be used with caution, since NXP800 was found to be a BCRP substrate
* Usage of seville oranges, grapefruit or grapefruit juice or products ≤ 7 days prior to registration and for the duration of NXP800 dosing
* Unwillingness to follow study related procedures
* Inability to provide informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mitesh J. Borad, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kuipers H, Larson JJ, Conboy CB, Ahn DH, Bekaii-Saab T, Wu C, Sonbol MB, Ilyas SI, Gores GJ, Smoot RL, Borad MJ. A Phase 1 study of the novel GCN2 kinase activator NXP800 in patients with advanced cholangiocarcinoma. Future Oncol. 2025 Sep;21(21):2723-2730. doi: 10.1080/14796694.2025.2539611. Epub 2025 Jul 28.
Related Links
Access external resources that provide additional context or updates about the study.
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2024-03613
Identifier Type: REGISTRY
Identifier Source: secondary_id
MC230406
Identifier Type: OTHER
Identifier Source: secondary_id
23-012778
Identifier Type: OTHER
Identifier Source: secondary_id
MC230406
Identifier Type: -
Identifier Source: org_study_id